NASDAQ: CMPXCompass Therapeutics Inc Stock
$1.97-0.01 (-0.51%)
Updated Oct 14, 2024
CMPX Price
$1.97
Fair Value Price
$0.18
Market Cap
$270.36M
52 Week Low
$0.77
52 Week High
$2.34
P/E
-5.46x
P/B
1.85x
P/S
161.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$850.00k
Earnings
-$47.24M
Gross Margin
100%
Operating Margin
-5,557.88%
Profit Margin
-5,557.9%
Debt to Equity
0.07
Operating Cash Flow
-$43M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CMPX Overview
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat multiple human diseases. Its product candidates include CTX-009, in Phase II clinical trials for biliary tract cancers and Phase Ib clinical trial for colorectal and ovarian cancer, and CTX-471, in Phase I clinical trials for patients with solid tumors (small cell lung cancer and melanoma). Compass Therapeutics was founded in 2014 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CMPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CMPX ($1.97) is overvalued by 1,009.62% relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CMPX ($1.97) is not significantly undervalued (1,009.62%) relative to our estimate of its Fair Value price of $0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMPX due diligence checks available for Premium users.
Be the first to know about important CMPX news, forecast changes, insider trades & much more!
CMPX News
Valuation
CMPX fair value
Fair Value of CMPX stock based on Discounted Cash Flow (DCF)
Price
$1.97
Fair Value
$0.18
Overvalued by
1,012.44%
CMPX ($1.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMPX ($1.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMPX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CMPX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.46x
Industry
-124.07x
Market
27.44x
CMPX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.85x
Industry
6.12x
CMPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CMPX's financial health
Profit margin
Revenue
$850.0k
Net Income
-$13.1M
Profit Margin
-1,538.4%
CMPX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CMPX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$155.6M
Liabilities
$9.5M
Debt to equity
0.07
CMPX's short-term assets ($153.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMPX's short-term assets ($153.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.8M
Investing
$6.5M
Financing
$1.0k
CMPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CMPX vs Biotech Stocks
Compass Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.